In addition, a clinical trial has shown encouraging response and overall survival rates for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) treated with nivolumab(anti-PD-1) and azacitidine, which suggested that nivolumab in combination with azacitidine appears to be a safe and effective treatment for AML (188). The gene discussed is PDCD1; the disease is acute myeloid leukemia.